The MOTHERS Act: Thalidomide Revisited?

by Fred A. Baughman, Jr., MD** & Amy Philo* SAN DIEGO, May 23 /PRNewswire/ -- The Richmond (VA) Times-Dispatch reported that on Mother's Day, May 10, 1998, Sharon Alley stabbed her eight month old daughter, Brooke in the heart, killing her. Months before, Alley was prescribed Pax...

U of Minnesota study finds thalidomide shows promise for treatment of recurrent ovarian cancer

Thalidomide, a drug blamed in the 1950s for causing birth defects, is now showing promise as a safe and effective treatment for women with recurrent ovarian cancer, according to a study led by a University of Minnesota Cancer Center researcher. Levi Downs, Jr., M.D., principal investigator for th...

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

...ujimoto Pharmaceutical Receives Approval to Market thalidomide II-37 Celgene Obtains Health Canada Approval f...l II-39 European Commission Grants Approval of thalidomide for Multiple Myeloma II-39 EMEA Issues Positive Opinion for thalidomide Use in Multiple Myeloma II-39 Global Regul...

Treatments after prostate surgery reported in the Journal of Urology

... disease. Researchers investigated the addition of thalidomide to intermittent ADT in a double-blind, placebo-con...nts were first given ADT for 6 months, followed by thalidomide or placebo until their PSA increased (Oral Phase A... median time to PSA increase was 15 months for the thalidomide patients versus 9.6 months for placebo. The next p...

Combo Therapy Helps Multiple Myeloma Patients

...d counts. In most patients, these side effects were mild. Pomalidomide, also called CC-4047, belongs to the same class of immunomodulatory drugs as thalidomide and lenalidomide, both of which have been approved by the U.S. Food and Drug Administration for use with dexamethasone for multiple myeloma patients w...

Drug combination improves or stabilizes disease for relapsed multiple myeloma patients

...7, is the latest in the class of immunomodulatory agents that also includes thalidomide and lenalidomide. Multiple myeloma ( http://www.mayoclinic.org/multiple...ancer cells. The Food and Drug Administration (FDA) has approved the use of thalidomide and lenalidomide to be given with dexamethasone for previously treated case...

Thalidomide Continues to Show Benefits Against Myeloma

...ers exploring the benefits of the once-banned drug thalidomide for patients with myeloma have learned a lesson th... too early. Earlier findings showed that adding thalidomide into therapy regimens increased the odds of a comp... of eight years, overall survival in people taking thalidomide was, in fact, extended, although most significantl...

Duke chemist has new way to tell right from left

...two versions has the desired effect; the other is at best useless and sometimes even harmful. For example, side effects from the morning sickness drug thalidomide resulted in profound birth defects because one shape of the molecule was therapeutic and the other was dangerous. Don Coltart, an assistant profe...

Another way to grow blood vessels

...es have developed a number of drugs that manipulate the angiogenic pathway in both directions. Among them are anti-angiogenic cancer drugs, including thalidomide and Avastin, which are designed to starve tumors by blocking the formation of blood vessels. Avastin is also used to dampen the abnormal growth of sma...

Scoring system identifies MDS patients who have low-risk disease but a poor prognosis

... planned at M. D. Anderson. In the past three years, therapy for MDS has improved significantly, with approval of three new drugs: lenalidomide, a thalidomide derivative indicated for some patients, and two demethylating agents that turn on genes by removing chemical "off switches" that block gene expression...

Thalidomide in Medical Technology

Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75

Phase III Clinical Data on Thalidomide in Multiple Myeloma Presented at the American Society of Clinical Oncology 43rd Annual Meeting CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Pharmion Corporation today reported the final results of a Phase III study demonstrating that the addition of Thali...

Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting

...for one year. All patients enrolled in the Phase 2 trial have relapsed following treatment with bortezomib and an immunomodulatory agent, such as thalidomide or lenalidomide, and were refractory to their last treatment. Eighty percent of patients received at least four prior treatments. Of 26 patients enr...

Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting

...methasone); 98% of patients were previously treated with dexamethasone; 99% of patients were previously treated with lenalidomide (Revlimid(R)) and/or thalidomide (Thalomid(R)); and 57% of patients had prior stem cell transplant. No unexpected adverse events have been seen. Toxicities were manageable with suppor...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

...methasone); 98% of patients were previously treated with dexamethasone; 98% of patients were previously treated with lenalidomide (Revlimid(R)) and/or thalidomide (Thalomid(R)); and 57% of patients had prior stem cell transplant. No unexpected adverse events have been seen. Toxicities were manageable with suppo...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

...D), as well as in another study comparing VELCADE, thalidomide and dexamethasone (VcTD) with thalidomide and dexamethasone (TD). These data were presented .../m(2) of VELCADE on days 1, 4, 8 and 11; 200 mg of thalidomide daily and 40 mg of dexamethasone on days 1, 2, 4, ...

Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma

... rate after four cycles of carfilzomib. All patients enrolled in the trial have received prior treatment(s) with bortezomib and either lenalidomide or thalidomide and are refractory to their last treatment. A second open-label, multi-center Phase 2 trial of single-agent carfilzomib in relapsed multiple myeloma...

Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency

... The marketing authorization application (MAA) for thalidomide Pharmion was submitted to the EMEA in January 2007...thorization would be granted to Pharmion to market thalidomide Pharmion for first line multiple myeloma in the 27...his recommendation by the EMEA for the approval of thalidomide in the treatment of first line multiple myeloma, a...

Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting

... -- Bortezomib in Combination with Pegylated Liposomal Doxorubicin and thalidomide (VDT) for the Treatment of Previously Untreated Multiple Myeloma - Ashe... -- Pegylated Liposomal Doxorubicin (PLD), Dexamethasone and Low Dose thalidomide (DDt): An Active Regimen in the Frontline Therapy for Multiple Myeloma ...

New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma

...ral presentation session: Monday 10 December, 1:30 p.m. -- VELCADE, thalidomide and Dexamethasone (VTD) versus thalidomide Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Tra...

Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies

...ree years after diagnosis. However, within the last decade, a group of new therapies has been developed and approved for use in MM patients, including thalidomide (Thalidomid(R)), lenalidomide (Revlimid(R)), and bortezomib (Velcade(R)). Used alone or paired with traditional chemotherapy, these drugs have been sh...

Thalidomide in Biological News

Separating the good from the bad

...hiral molecule causing widespread harm occurred in the 1950s, when the drug thalidomide was given to pregnant women to prevent morning sickness. One naturally occurring formor isomerof thalidomide reduces nausea; the other causes birth defects. In another commonly used ch...

Why were the HIV prevention trials in commercial sex workers abandoned?

...ogress of at least two important clinical trials of tenofovir as PREP and brought negative attention to tenofovir, somewhat similar to that visited on thalidomide more than four decades ago," say two researchers in an essay in the open access global health journal PLoS Medicine. The dramatic protest at the XV ...

15-year hunt finds cause of pseudothalidomide syndrome

...s that resemble those of babies whose mothers took thalidomide during pregnancy. The discovery, which is report...with Roberts syndrome and those whose mothers took thalidomide suggest similar underlying biology, Jabs notes. Although there's some evidence that thalidomide prevents blood vessel growth, it's not clear why. ...

Thalidomide in Biological Technology

Pharmion Corporation Announces 2007 Operating Results

...ared to $11.6 million in 2006. Named patient and compassionate use sales of thalidomide totaled $81.7 million in 2007, compared to $77.5 million in 2006. Fourth ...period in 2006. Fourth quarter named patient and compassionate use sales of thalidomide totaled $21.0 million, compared to $18.8 million in the fourth quarter of 2...

Millennium Over-Delivers on 2007 Goals and Financial Guidance

...methasone (VcTD), as induction therapy prior to SCT, showed a dramatic fourfold increase in complete remission rate when compared to thalidomide and dexamethasone (TD), the most commonly used induction regimen in the U.S. for patients eligible for SCT. These results from 256 ...